Like_老虎社区_美港股上老虎

PG123
2021-12-01

Pfizer seeks U.S. authorization of COVID-19 booster shots for 16, 17 year olds

Nov 30 (Reuters) - Pfizer Inc's Chief Executive Officer Albert Bourla said on Tuesday the company ha

Pfizer seeks U.S. authorization of COVID-19 booster shots for 16, 17 year olds

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":609403460,"tweetId":"609403460","gmtCreate":1638315056962,"gmtModify":1638315057288,"author":{"id":3575178537395503,"authorId":3575178537395503,"authorIdStr":"3575178537395503","name":"PG123","avatar":"https://static.tigerbbs.com/44ec19c217bfeef30ef380b542fb98a2","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":72,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like</p></body></html>","htmlText":"<html><head></head><body><p>Like</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/609403460","repostId":2188321615,"repostType":4,"repost":{"id":"2188321615","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1638314566,"share":"https://www.laohu8.com/m/news/2188321615?lang=&edition=full","pubTime":"2021-12-01 07:22","market":"us","language":"en","title":"Pfizer seeks U.S. authorization of COVID-19 booster shots for 16, 17 year olds","url":"https://stock-news.laohu8.com/highlight/detail?id=2188321615","media":"Reuters","summary":"Nov 30 (Reuters) - Pfizer Inc's Chief Executive Officer Albert Bourla said on Tuesday the company ha","content":"<p>Nov 30 (Reuters) - Pfizer Inc's Chief Executive Officer Albert Bourla said&nbsp;on Tuesday the company has submitted a request to the U.S. Food and Drug Administration seeking the authorization for its COVID-19 booster doses for use in 16- and 17-year olds.</p>\n<p>Last week, U.S. regulators expanded the eligibility for a booster dose of Pfizer and partner BioNTech's vaccine to all adults 18 and over, to be given at least six months after the second shot.</p>\n<p>If given the go-ahead, Pfizer's booster vaccine will be the first to be cleared for use in the younger age group.</p>\n<p>The Wall Street Journal reported&nbsp;on Monday that the FDA could approve Pfizer's booster doses for 16- and 17-year olds as soon as next week.</p>\n<p>U.S. government and the country's health regulators are currently pushing for wider vaccinations to prevent the spread of the highly infectious Omicron coronavirus variant, which was first detected in southern Africa.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer seeks U.S. authorization of COVID-19 booster shots for 16, 17 year olds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer seeks U.S. authorization of COVID-19 booster shots for 16, 17 year olds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-01 07:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nov 30 (Reuters) - Pfizer Inc's Chief Executive Officer Albert Bourla said&nbsp;on Tuesday the company has submitted a request to the U.S. Food and Drug Administration seeking the authorization for its COVID-19 booster doses for use in 16- and 17-year olds.</p>\n<p>Last week, U.S. regulators expanded the eligibility for a booster dose of Pfizer and partner BioNTech's vaccine to all adults 18 and over, to be given at least six months after the second shot.</p>\n<p>If given the go-ahead, Pfizer's booster vaccine will be the first to be cleared for use in the younger age group.</p>\n<p>The Wall Street Journal reported&nbsp;on Monday that the FDA could approve Pfizer's booster doses for 16- and 17-year olds as soon as next week.</p>\n<p>U.S. government and the country's health regulators are currently pushing for wider vaccinations to prevent the spread of the highly infectious Omicron coronavirus variant, which was first detected in southern Africa.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4550":"红杉资本持仓","PFE":"辉瑞","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188321615","content_text":"Nov 30 (Reuters) - Pfizer Inc's Chief Executive Officer Albert Bourla said on Tuesday the company has submitted a request to the U.S. Food and Drug Administration seeking the authorization for its COVID-19 booster doses for use in 16- and 17-year olds.\nLast week, U.S. regulators expanded the eligibility for a booster dose of Pfizer and partner BioNTech's vaccine to all adults 18 and over, to be given at least six months after the second shot.\nIf given the go-ahead, Pfizer's booster vaccine will be the first to be cleared for use in the younger age group.\nThe Wall Street Journal reported on Monday that the FDA could approve Pfizer's booster doses for 16- and 17-year olds as soon as next week.\nU.S. government and the country's health regulators are currently pushing for wider vaccinations to prevent the spread of the highly infectious Omicron coronavirus variant, which was first detected in southern Africa.","news_type":1},"isVote":1,"tweetType":1,"viewCount":418,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Pfizer seeks U.S. authorization of COVID-19 booster shots for 16, 17 year olds

评论（2）

热议股票